Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Tipo de documento
País/Região como assunto
Ano de publicação
Intervalo de ano de publicação
1.
Curr Treat Options Oncol ; 16(3): 337, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25782687

RESUMO

Despite early renal carcinoma diagnosis is more frequent nowadays, ~25-30 % of patients have metastatic disease at presentation and another ~30 % develop recurrent or metastatic disease after radical treatment for localized disease. In recent years, treatment of renal carcinoma is increasing in complexity due to the inclusion of a number of effective systemic treatments prolonging survival and increasing the therapeutic strategies for tumor debulking, or even achieving surgical complete responses and prolonged disease-free intervals. Initial multimodal approaches with immunotherapeutic agents are now being validated in patients treated with the new-targeted agents. Patients are now able to receive an optimal therapeutic strategy seeking a longer survival with an acceptable life quality and avoiding unnecessary comorbidities. In this context and as an initial therapeutic approach, it is imperative to promote patients' selection with established prognostic models within a multidisciplinary team to assess the recommendation of a cytoreductive nephrectomy (CN), metastasectomy, and/or systemic treatment. In the context of mRCC, when feasible and in patients with favorable prognostic factors, the strategy should be to consider a CN or metastasectomy for tumor debulking in order to achieve free intervals of prolonged disease. By contrast, it is recommended to evaluate whether to perform a biopsy for histological diagnosis without nephrectomy in the following situations: high surgical risk, bulky metastatic disease or in specific sites (brain or liver) or ECOG PS 3/4. The following review covers from initial to recent studies on the integration of systemic treatment and surgery in the context of metastatic disease for an optimal multimodal management in renal carcinoma.


Assuntos
Carcinoma de Células Renais/terapia , Imunoterapia/métodos , Neoplasias Renais/terapia , Metastasectomia , Nefrectomia , Carcinoma de Células Renais/imunologia , Carcinoma de Células Renais/mortalidade , Humanos , Imunoterapia/tendências , Comunicação Interdisciplinar , Neoplasias Renais/imunologia , Neoplasias Renais/mortalidade , Metastasectomia/tendências , Nefrectomia/tendências , Seleção de Pacientes , Prognóstico , Qualidade de Vida , Resultado do Tratamento
2.
PLoS One ; 7(10): e47128, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23071734

RESUMO

Tropical regions are facing increasing atmospheric inputs of nutrients, which will have unknown consequences for the structure and functioning of these systems. Here, we show that Neotropical montane rainforests respond rapidly to moderate additions of N (50 kg ha(-1) yr(-1)) and P (10 kg ha(-1) yr(-1)). Monitoring of nutrient fluxes demonstrated that the majority of added nutrients remained in the system, in either soil or vegetation. N and P additions led to not only an increase in foliar N and P concentrations, but also altered soil microbial biomass, standing fine root biomass, stem growth, and litterfall. The different effects suggest that trees are primarily limited by P, whereas some processes-notably aboveground productivity--are limited by both N and P. Highly variable and partly contrasting responses of different tree species suggest marked changes in species composition and diversity of these forests by nutrient inputs in the long term. The unexpectedly fast response of the ecosystem to moderate nutrient additions suggests high vulnerability of tropical montane forests to the expected increase in nutrient inputs.


Assuntos
Ecossistema , Nitrogênio/farmacologia , Fósforo/farmacologia , Árvores , Biomassa , Equador , Fertilizantes , Folhas de Planta , Raízes de Plantas , Solo , Árvores/crescimento & desenvolvimento , Clima Tropical
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA